Cipla targets USD 1 billion revenues from domestic market

Cipla is looking for a billion-dollar consolidated revenue for the domestic market in FY19. The company reported revenues of Rs. 15,219 crore, growing 6 percent, with income from the India operations seeing a 6.3 percent jump at Rs. 5687 crore in FY18. The drug maker expects the in-licensing deals with innovator companies, focus on certain therapeutic segments and sales force productivity optimisation measures to aid growth in India. This financial year, the focus remained on strengthening the company’s portfolio and deepening its presence in priority markets. The focus for next year will be to continue on the growth trajectory in key markets.

An enabling resolution has been taken, implies that the company will not be doing deals worth Rs. 4000 crore. As and when they become available, they will go ahead with an acquisition, but will not buy unless a synergy value in the transaction is seen. Last year the company had taken an enabling resolution to raise funds of about Rs. 2000 crore of debt and Rs. 2000 crore of equity. The company is also looking at consolidating its position in South Africa, the United States of America, Europe, and emerging markets. The company is planning significant investments in R&D to build a strong pipeline, with over 20 targeted filings in FY19. This year will also see higher investments toward clinical trials for key respiratory assets and focus on building specialty assets.